Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy †

The epidermal growth factor receptor (EGFR) has evolved over years into a main molecular target for the treatment of different cancer entities. In this regard, the anti-EGFR antibody cetuximab has been approved alone or in combination with: (a) chemotherapy for treatment of colorectal and head and neck squamous cell carcinoma and (b) with external radiotherapy for treatment of head and neck squamous cell carcinoma. The conjugation of radionuclides to cetuximab in combination with the specific targeting properties of this antibody might increase its therapeutic efficiency. This review article gives an overview of the preclinical studies that have been performed with radiolabeled cetuximab for imaging and/or treatment of different tumor models. A particularly promising approach seems to be the treatment with therapeutic radionuclide-labeled cetuximab in combination with external radiotherapy. Present data support an important impact of the tumor micromilieu on treatment response that needs to be further validated in patients. Another important challenge is the reduction of nonspecific uptake of the radioactive substance in metabolic organs like liver and radiosensitive organs like bone marrow and kidneys. Overall, the integration of diagnosis, treatment and monitoring as a theranostic approach appears to be a promising strategy for improvement of individualized cancer treatment.

• Publication year

  2014

• Venue

  Pharmaceuticals

• Publication date

  2014-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3390/ph7030311PMID 24603603PMCID 3978494
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Imaging EGFR and HER2 by PET and SPECT: A Review

  2014cited by this paper
• Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

  2014cited by this paper
• Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential.

  2014cited by this paper
• 111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.

  2013cited by this paper
• Efficacy of intensity-modulated radiotherapy combined with chemotherapy or surgery in locally advanced squamous cell carcinoma of the head-and-neck

  2013cited by this paper
• DAHANCA 19: First results of a randomized phase III study of the importance of the EGFR-inhibitor zalutumumab for the outcome of primary curative radiotherapy for squamous cell carcinoma of the head and neck

  2013cited by this paper
• STAT1 and STAT3 in Tumorigenesis: Two Sides of the Same Coin?

  2013cited by this paper
• Preparation and quality control and biodistribution studies of [90Y]-DOTA-cetuximab for radioimmunotherapy

  2013cited by this paper
• H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy.

  2013cited by this paper
• Synthesis and application of a novel cysteine-based DTPA-NCS for targeted radioimmunotherapy.

  2013cited by this paper
• Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.

  2013cited by this paper
• Integration of radiation oncology with surgery as combined-modality treatment.

  2013cited by this paper
• Value of 131I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature

  2013cited by this paper
• Placental Growth Factor (PlGF)–Specific Uptake in Tumor Microenvironment of 89Zr-Labeled PlGF Antibody RO5323441

  2013cited by this paper
• Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody

  2013influential reference
• Influence of Macrocyclic Chelators on the Targeting Properties of 68Ga-Labeled Synthetic Affibody Molecules: Comparison with 111In-Labeled Counterparts

  2013cited by this paper
• The Role of p53 in Combination Radioimmunotherapy with 64Cu-DOTA-Cetuximab and Cisplatin in a Mouse Model of Colorectal Cancer

  2013cited by this paper
• Inactivation of HNSCC Cells by 90Y-Labeled Cetuximab Strictly Depends on the Number of Induced DNA Double-Strand Breaks

  2013cited by this paper
• Cetuximab: still an option in the treatment of pancreatic cancer?

  2013cited by this paper
• Alternate dosing of cetuximab for patients with metastatic colorectal cancer.

  2013cited by this paper
• Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice.

  2013cited by this paper
• Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models.

  2013cited by this paper
• Quantitative Comparison of PET and Bremsstrahlung SPECT for Imaging the In Vivo Yttrium-90 Microsphere Distribution after Liver Radioembolization

  2013cited by this paper
• Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor.

  2013influential reference
• The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo.

  2013cited by this paper
• Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

  2013cited by this paper
• Positron emission tomography imaging of tumor angiogenesis with a 66Ga-labeled monoclonal antibody.

  2012cited by this paper
• The road to resistance: EGFR mutation and cetuximab

  2012cited by this paper
• Recent trends in antibody-based oncologic imaging.

  2012influential reference
• Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.

  2012cited by this paper
• Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro.

  2012cited by this paper
• The Application of FDG-PET as Prognostic Indicators in Head and Neck Squamous Cell Carcinoma.

  2012cited by this paper
• New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)

  2012cited by this paper
• Evaluation and comparison of human absorbed dose of 90Y-DOTA-Cetuximab in various age groups based on distribution data in rats

  2012cited by this paper
• Cellular and molecular properties of 90Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro

  2012cited by this paper
• Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody.

  2012cited by this paper
• Flow cytometric cell‐based assay to preselect antibody constructs for radionuclide conjugation

  2012cited by this paper
• Noninvasive small-animal PET of trastuzumab-mediated EGFR down-regulation with 68Ga-Vec(Fab')2

  2012cited by this paper
• Cetuximab plus radiotherapy in patients with unresectable locally advanced squamous cell carcinoma of head and neck region--a open labelled single arm phase II study.

  2011cited by this paper
• Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a head‐and‐neck squamous cell carcinoma model

  2011cited by this paper
• Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression.

  2011cited by this paper
• A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC).

  2011cited by this paper
• Quantitative imaging of 124I and 86Y with PET

  2011cited by this paper
• Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET

  2011cited by this paper
• Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts

  2011cited by this paper
• In vitro and in vivo pre-clinical analysis of a F(ab')2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers

  2011cited by this paper
• Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC).

  2011cited by this paper
• HER1-Targeted 86Y-Panitumumab Possesses Superior Targeting Characteristics than 86Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts

  2011influential reference
• Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma.

  2011cited by this paper
• Positron Emission Tomography Imaging of CD105 Expression with a 64Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA

  2011cited by this paper
• Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets

  2011cited by this paper
• Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

  2011cited by this paper
• PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab

  2010cited by this paper
• Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma

  2010influential reference
• Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

  2010cited by this paper
• 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors.

  2010cited by this paper
• Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1

  2010cited by this paper
• Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia

  2010cited by this paper
• To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.

  2010cited by this paper
• 131I therapy in patients with benign thyroid disease does not conclusively lead to a higher risk of subsequent malignancies

  2010cited by this paper
• Immuno-PET Quantitation of de2-7 Epidermal Growth Factor Receptor Expression in Glioma Using 124I-IMP-R4–Labeled Antibody ch806

  2010cited by this paper
• Preparation, Biological Evaluation, and Pharmacokinetics of the Human Anti-HER1 Monoclonal Antibody Panitumumab Labeled with 86Y for Quantitative PET of Carcinoma

  2010cited by this paper
• Radiolabeled Cetuximab plus Whole-Brain Irradiation (WBI) for the Treatment of Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)

  2010cited by this paper
• In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies.

  2010cited by this paper
• Effect of cetuximab and fractionated irradiation on tumour micro-environment.

  2010cited by this paper
• J Nucl Med

  2010cited by this paper
• p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging

  2009cited by this paper
• Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges.

  2009cited by this paper
• Radioactive EGFR antibody cetuximab in multimodal cancer treatment: stability and synergistic effects with radiotherapy.

  2009cited by this paper
• In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies

  2009cited by this paper
• Evaluation of quantitative planar 90Y bremsstrahlung whole-body imaging

  2009cited by this paper
• Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent

  2009cited by this paper
• PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models

  2009cited by this paper
• Copper-64 Radiopharmaceuticals for PET Imaging of Cancer: Advances in Preclinical and Clinical Research

  2009cited by this paper
• Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients

  2009cited by this paper
• Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.

  2009cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy

  2009cited by this paper
• Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

  2009cited by this paper
• Modulating the tumor microenvironment to increase radiation responsiveness

  2009cited by this paper
• In Vivo Biodistribution, PET Imaging, and Tumor Accumulation of 86Y- and 111In-Antimindin/RG-1, Engineered Antibody Fragments in LNCaP Tumor–Bearing Nude Mice

  2009cited by this paper
• Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I Study

  2009cited by this paper
• Pharmacotherapy of head and neck squamous cell carcinoma

  2009cited by this paper
• Receptor-Binding, Biodistribution, and Metabolism Studies of 64Cu-DOTA-Cetuximab, a PET-Imaging Agent for Epidermal Growth-Factor Receptor-Positive Tumors

  2008cited by this paper
• Quantitative Serial Imaging of an 124I Anti-CEA Monoclonal Antibody in Tumor-Bearing Mice

  2008cited by this paper
• Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET

  2008cited by this paper
• Non-Invasive PET Imaging of EGFR Degradation Induced by a Heat Shock Protein 90 Inhibitor

  2008cited by this paper
• The role of p53 in the trafficking of copper-64 to tumor cell nuclei

  2008cited by this paper
• 213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model.

  2008cited by this paper
• Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

  2008cited by this paper
• Correlating EGFR Expression with Receptor-Binding Properties and Internalization of 64Cu-DOTA-Cetuximab in 5 Cervical Cancer Cell Lines

  2008cited by this paper
• Platinum-based chemotherapy plus cetuximab in head and neck cancer.

  2008cited by this paper
• Bifunctional chelates for metal nuclides.

  2008cited by this paper
• Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications.

  2008cited by this paper
• Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment.

  2008cited by this paper
• Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.

  2007cited by this paper
• Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule.

  2007cited by this paper
• 177Lu-labeled-VG76e monoclonal antibody in tumor angiogenesis: A comparative study using DOTA and DTPA chelating systems

  2007cited by this paper
• Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody

  2007cited by this paper
• Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies

  2007cited by this paper

• Radiation dose estimation of human organs for 177Lu-anti-EGFR-PAMAM complex

  2024cites this paper
• Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review

  2024cites this paper
• Preparation, quality control, and absorbed dose estimation of 89Zr-DFO-Cetuximab for imaging of EGFR-expressing tumors

  2024cites this paper
• Development of a Neopentyl 211At‐Labeled Activated Ester Providing In Vivo Stable 211At‐Labeled Antibodies for Targeted Alpha Therapy

  2024cites this paper
• RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using 47Sc-conjugated cetuximab

  2023cites this paper
• Monoclonal Antibodies and Immuno-PET Imaging: An Overview

  2023cites this paper
• The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials

  2023cites this paper
• Synthesis and preclinical evaluation of rhenium and technetium-99m "4 + 1" mixed-ligand complexes bearing quinazoline derivatives as potential EGFR imaging agents.

  2022cites this paper
• Fluorescence Molecular Targeting of Colon Cancer to Visualize the Invisible

  2022cites this paper
• Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC)

  2021cites this paper
• 89Zr as a promising radionuclide and it’s applications for effective cancer imaging

  2021cites this paper
• Exploring the Application of Bifunctional Metal Chelators in Treating Triple-Negative Breast Cancer

  2021cites this paper
• Principle and Applications of Immunodiagnostics Using Radioisotope as Tracers

  2020cites this paper
• Prospects and Clinical Perspectives of Total-Body PET Imaging Using Plastic Scintillators.

  2020cites this paper
• Three-Dimensional Cell Culture Systems in Radiopharmaceutical Cancer Research

  2020cites this paper
• Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer

  2020cites this paper
• Nanotechnology for oral drug delivery and targeting

  2020cites this paper
• Radiotherapy enhances uptake and efficacy of 90Y-Cetuximab: a preclinical trial.

  2020cites this paper
• Chemotherapeutic Effectiveness of Combining Cetuximab for Metastatic Colorectal Cancer Treatment: A System Review and Meta-Analysis

  2020cites this paper
• Nanotechnology in Targeted Drug Delivery and Therapeutics

  2019cites this paper
• Utilizing Immunopet To Measure Tumor Response To Treatment In Breast Cancer

  2019cites this paper
• Fluorescence Lifetime-Based Tumor Contrast Enhancement Using an EGFR Antibody–Labeled Near-Infrared Fluorophore

  2019influential citation
• Radioimmunotherapy in Head and Neck Cancer

  2018cites this paper
• Development of radioimmunoconjugate for diagnosis and management of head-and-neck subclinical cancer and colorectal carcinoma

  2018cites this paper
• PET of EGFR with 64Cu-cetuximab-F(ab′)2 in mice with head and neck squamous cell carcinoma xenografts

  2018cites this paper
• Radiolabeled F(ab′)2-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models

  2018cites this paper
• EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer.

  2018cites this paper
• Understanding the inflammation-cancer transformation in the development of primary liver cancer

  2018cites this paper
• Noninvasive assessment of characteristics of novel anti-HER2 antibodies by molecular imaging in a human gastric cancer xenograft-bearing mouse model

  2018cites this paper
• Radioactive Transition Metals for Imaging and Therapy.

  2018cites this paper
• Radiolabeling, Characteristics and NanoSPECT/CT Imaging of 188Re-cetuximab in NCI-H292 Human Lung Cancer Xenografts

  2018cites this paper
• Clinically Relevant Radioactive Dose Formulation of 177 Lu-Labeled Cetuximab-Fab Fragment for Potential Use in Cancer Theranostics

  2018cites this paper
• Imaging of Tumor Characteristics and Molecular Pathways With PET: Developments Over the Last Decade Toward Personalized Cancer Therapy.

  2018cites this paper
• Exploring pitfalls of 64Cu-labeled EGFR-targeting peptide GE11 as a potential PET tracer

  2018cites this paper
• Novel Tumor Pretargeting System Based on Complementary l-Configured Oligonucleotides.

  2017cites this paper
• Immuno-PET imaging based radioimmunotherapy in head and neck squamous cell carcinoma model

  2017cites this paper
• Nanofitin as a New Molecular-Imaging Agent for the Diagnosis of Epidermal Growth Factor Receptor Over-Expressing Tumors.

  2017cites this paper
• An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment

  2017cites this paper
• Nanoparticles for radiooncology: Mission, vision, challenges.

  2017cites this paper
• SPECT imaging evaluation of 111indium‐chelated cetuximab for diagnosing EGFR‐positive tumor in an HCT‐15‐induced colorectal xenograft

  2017cites this paper
• [Radionuclide teranostic of malignancies].

  2016cites this paper
• Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model

  2016cites this paper
• Recent progress in protein-protein interaction study for EGFR-targeted therapeutics

  2016cites this paper
• Application of infrared‐based molecular imaging to a mouse model with head and neck cancer

  2016cites this paper
• Targeted imaging of EGFR overexpressed cancer cells by brightly fluorescent nanoparticles conjugated with cetuximab.

  2016cites this paper
• Design of antibody-functionalized carbon nanotubes filled with radioactivable metals towards a targeted anticancer therapy.

  2016cites this paper
• In vivo detection of small tumour lesions by multi-pinhole SPECT applying a 99mTc-labelled nanobody targeting the Epidermal Growth Factor Receptor

  2016cites this paper
• Relevance of radiobiological concepts in radionuclide therapy of cancer

  2016cites this paper
• Immunological Effect of Anti-Epidermal Growth Factor Receptor (EGFR)Antibodies in Squamous Cell Carcinoma of the Head and Neck (HNSCC):the Present and the Future

  2016cites this paper
• (90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation.

  2016cites this paper
• Novel Single-Photon-Emitting Radiopharmaceuticals for Diagnostic Applications

  2016cites this paper
• PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.

  2016cites this paper
• In vivo imaging of the voltage-gated potassium channel Kv10.1 utilizing SPECT in combination with radiolabeled antibodies

  2015cites this paper
• Towards molecular imaging for personalized therapy of patients with colorectal cancer liver metastasis

  2015cites this paper
• PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging

  2015cites this paper
• Improving external beam radiotherapy by combination with internal irradiation.

  2015influential citation
• Isolating epidermal growth factor receptor overexpressing carcinoma cells from human whole blood by bio‐ferrography

  2015cites this paper
• In vivo demonstration of an active tumor pretargeting approach with peptide nucleic acid bioconjugates as complementary system

  2015cites this paper
• Epidermal growth factor receptor imaging in human head and neck cancer xenografts

  2015cites this paper
• Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.

  2014cites this paper
• An EGFR Targeted PET Imaging Probe for the Detection of Colonic Adenocarcinomas in the Setting of Colitis

  2014cites this paper
• Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.

  2014cites this paper
• Matching the Decay Half-Life with the Biological Half-Life: ImmunoPET Imaging with 44Sc-Labeled Cetuximab Fab Fragment

  2014cites this paper
• Pancreatic Cancer Using Multispectral Optoacoustic Tomography Targeted Noninvasive Imaging of EGFR-Expressing Orthotopic

  2014cites this paper
• Targeted noninvasive imaging of EGFR-expressing orthotopic pancreatic cancer using multispectral optoacoustic tomography.

  2014cites this paper
• Molecular imaging of epidermal growth factor receptor in lung cancer

  2014cites this paper
• Pharmaceuticals—Special Issue on Radiopharmaceutical Chemistry between Imaging and Endoradiotherapy

  2014cites this paper
• Placental Growth Factor (PlGF)–Specific Uptake in Tumor Microenvironment of 89Zr-Labeled PlGF Antibody RO5323441

  2013cites this paper
• - I m a g i n g s i n g P a s t i c S c i n t i l l a t o r s

  year unknowncites this paper